Lille, France, and Cambridge, Mass., September 6th, 2011- After critical review by independent experts, the results of the GFT505-209-3 and GFT505-209-4 studies are published in « Diabetes Care », an official international scientific journal of the ADA (American Diabetes Association). – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focused on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, announced the publication in « Diabetes Care » of a scientific article presenting the results of the GFT505-210-3 and GFT505-210-4 clinical trials.The article reports the beneficial effects of GFT505 on glucose and lipid metabolism, inflammation, and liver function in patients with abdominal obesity, mixed dyslipidemia, and/or pre-diabetes. After critical review and approval by independent experts, the manuscript is published under the title ‘Effects of the new dual PPARα/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism » (B. Cariou, Y. Zair, B. Staels, and E. Bruckert, Diabetes Care, 34: 2008-2014) in the category « Emerging Treatments and Technologies’...
[...]
...About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI, SERVIER, …), to address these major public health concerns and their unmet medical needs. GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT’s lead proprietary compound, GFT505, that is currently in Phase II... [PDF] GENFIT's Press Release - PDF du communiqué de presse GENFIT -
